IP Library Granted Patent US 8,232,387
Granted Patent B2
US 8,232,387 · App. 12/857,939 · Granted Jul 31, 2012

Process for the preparation of cladribine

Assignee: ScinoPharm Taiwan, Ltd.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,232,387
App. No.
12/857,939
Granted
Jul 31, 2012
Kind
B2
Abstract

A process for the preparation of cladribine of API grade is provided by direct coupling of O-protected 2-deoxy-ribofuranose with silylated 2-chloroadenine followed by deprotection of the resultant protected nucleoside in a separate step and then a purification step. Following the coupling, the desired N-9-glycosylated β-anomer of the nucleoside is directly isolated as a solid from the coupling reaction mixture by filtration in relatively high purity and yield, and it does not require purification.

Claims (17)

1. A process for making cladribine of formula I

comprising:

a) coupling a compound of formula II

wherein each of R 1 , R 2 and R 3 is independently alkyl, alkenyl, alkynyl or aryl, x is 0, 1 or 2, y is 2, 1 or 0, and R 4 is hydrogen or SiR 1 R 2 R 3 , with a protected 2-deoxy-ribofuranose of formula III

wherein each of R 6 and R 7 is independently a hydroxyl protecting group, and R 5 is a leaving group in an organic solvent and in the presence of a sulfonic acid based Lewis or Brønsted acid at a temperature of between about 0° C. to about reflux of the organic solvent to obtain a reaction mixture comprising a β-anomer of formula IV

wherein x′ is 0, 1 or 2, y′ is 2, 1 or 0;

b) selectively precipitating the β-anomer of formula IV from the reaction mixture to obtain a heterogeneous mixture in the presence of acetonitrile;

c) isolating the precipitated β-anomer of formula IV from the heterogeneous mixture to obtain isolated and substantially enriched β-anomer of formula IV; and

d) converting the isolated and substantially enriched β-anomer of formula IV to cladribine.

2. The process of claim 1 wherein the compound of formula II is prepared by silylating 2-chloroadenine with a silylating agent in an organic solvent or neat, wherein x is 0, 1, 2, y is 2, 1, 0, R 4 is hydrogen or SiR 1 R 2 R 3 , and when x is 2, y is 0, R 4 is SiR 1 R 2 R 3 .

3. The process of claim 2 wherein the silylating agent is N, O-bis(trimethylsilyl)trifluoroacetamide.

4. The process of claim 1 wherein the coupling step is carried out in the presence of a silylating agent.

5. The process of claim 1 wherein the hydroxy protecting group is a halo-substituted aroyl group.

6. The process of claim 1 wherein the leaving group is acetoxy.

7. The process of claim 1 wherein the organic solvent is selected from the group consisting of acetonitrile, tetrahydrofuran, dichloromethane, dichloroethane, toluene, hexamethyldisilazane, N, O-bis(trimethylsilyl)trifluoroacetamide, N,O-bis(trimethylsilyl)acetamide, and combinations thereof.

8. The process of claim 1 wherein the organic solvent is acetonitrile.

9. The process of claim 1 wherein prior to commencing the step of c), the process further comprises a step of maintaining the heterogeneous mixture formed in step b) at a temperature of 40 ° C. to 85 ° C. for at least 2 hours.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 17, 2010
From: HENSCHKE, JULIAN PAUL; ZHANG, XIAOHENG; CHU, GUODONG; MEI, LIJUN; CHEN, YUNG FA
To: SCINOPHARM (KUNSHAN) BIOCHEMICAL TECHNOLOGY CO., LTD.
Reel/Frame 024846/0962 →
Continuity (2)
Provisional Application 61234683 · Aug 18, 2009
Related Publication 20110046363A1 · Feb 24, 2011